Ben Venue's Bedford Labs will assume Cetus Ben Venue oncology product line.
Executive Summary
BEN VENUE TO BUY OUT CHIRON ONCOLOGY PRODUCTS JOINT VENTURE Cetus Ben Venue following Federal Trade Commission review of the transaction, which is expected to conclude in May, the companies announced April 22. Ben Venue's Bedford Labs generics business, which will assume the Cetus Ben Venue cancer drug injectable product line, will be able to ship products May 1, the company said.